Notably, recent studies in myelodysplastic syndromes reported PLCβ1 mRNA as being correlated with favorable clinical outcomes, whereas decreased PLCβ1 expression was associated with poor prognosis [105,106]. This evidence concerns the gene PLCB1 and myelodysplastic syndrome.